Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Method of altering the differentiation state of the cell

Subclass of:

435 - Chemistry: molecular biology and microbiology

435325000 - ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE

435375000 - Method of regulating cell metabolism or physiology

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100047911COMPOSITIONS AND METHODS FOR ISOLATION, PROPAGATION, AND DIFFERENTIATION OF HUMAN STEM CELLS AND USES THEREOF - The invention is directed to the field of human stem cells and includes methods and compositions for isolating, propagating, and differentiating human stem cells. The invention provides therapeutic uses of the methods and compositions, including autologous transplantation of treated cells into humans for treatment of Parkinson's and other neuronal disorders.02-25-2010
20130045534Methods of Deriving Differentiated Cells from Stem Cells - The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells.02-21-2013
20100112692Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides a method to increase the expression of markers associated with the pancreatic endocrine lineage.05-06-2010
20120244620COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF IMMATURE MONOCYTIC DENDRITIC CELLS - The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-1 and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided.09-27-2012
20130078721Cell Culture Medium for the Growth and Differentiation of Cells of the Hematopoietic Lineage - The present invention relates to a cell culture medium for the growth and/or differentiation of cells of the hematopoietic lineage, comprising: —insulin at a concentration of from 1 to 50 μg/ml; —transferrin at a concentration of from 100 μg/ml to 2000 μg/ml; and—plasma or serum at a concentration of from 1% to 30%.03-28-2013
20100041145TOLEROGENIC DENDRITIC CELLS, METHOD FOR THEIR PRODUCTION AND USES THEROF - The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity.02-18-2010
20130029418METHODS AND PRODUCTS FOR TRANSFECTION - The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.01-31-2013
20130029419Blood-Brain Barrier Model - A method of creating a multicellular blood-brain barrier model is disclosed. In one embodiment, the method comprises culturing primary brain microvascular endothelial cells or embryonic stem cell-derived endothelial cells upon a permeable support in the presence of neural progenitor cells.01-31-2013
20100093092METHOD FOR INDUCING PLURIPOTENCY IN CELLS - The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity.04-15-2010
20100093089DEDIFFERENTIATION OF ADULT MAMMALIAN CARDIOMYOCYTES INTO CARDIAC STEM CELLS - Dedifferentiation is a mechanism whereby specialized cells regain properties of their ancestors, including, in the extreme, stemness. We found that highly-purified cardiomyocytes isolated from adult mammalian hearts dedifferentiated rapidly when cultured in mitogen-rich medium. Such myocytes reentered the cell cycle and proliferated, expressing stem cell surface markers such as c-kit and early cardiac transcription factors including GATA and NKx2.5. These myocyte-derived cells (MDC) were capable of re-differentiating into myocytes and endothelial cells. Contrary to prevailing dogma, cardiomyocyte dedifferentiation yields proliferative cells expressing stem cell markers and capable of multilineage differentiation. Cardiomyocyte dedifferentiation is a potential source of endogenous stem cells in the adult heart.04-15-2010
20090305411RECOMBINANT ANTIBODIES AND IMMUNOCONJUGATES TARGETED TO CD-22 BEARING CELLS AND TUMORS - Methods and compositions relating to anti-CD22 antibodies with high binding affinity, and immunoconjugates comprising the anti-CD22 antibody linked to a therapeutic agent such as a 12-10-2009
20130071932CULTURE METHOD FOR CAUSING DIFFERENTIATION OF PLURIPOTENT MAMMALIAN CELLS - Provided is a method that achieves control of embryoid body size and can induce differentiation in a state where the embryoid body size is controlled, by using a cell culture chamber having a plurality of microchambers formed therein. A culture method for causing differentiation of pluripotent mammalian cells uses a cell culture chamber (03-21-2013
20130071931PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY - A method for hepatic differentiation of a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is presented. More specifically, a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is cultured for 1 to 4 weeks in the presence of a TGF-β inhibitor, whereby the hepatic differentiation of the stem cell is realized.03-21-2013
20120309088METHODS AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL - The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.12-06-2012
20110014703Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells into cells expressing markers characteristic of the pancreatic endocrine lineage that co-express PDX1, NKX6.1, but do not express CDX2 and NGN3.01-20-2011
20110014702Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells capable of producing insulin following transplantation into an animal.01-20-2011
20090298178GROWTH FACTORS FOR PRODUCTION OF DEFINITIVE ENDODERM - Disclosed herein are methods for generating endoderm lineage type cells derived from human pluripotent cells, such as human embryonic stem cells, by using various agents including, but not limited to, GDF8, GDF11 and GSK-3beta inhibitors. Also disclosed herein are endoderm lineage cell populations or compositions, such as populations or compositions comprising definitive endoderm and/or other definitive endoderm-derived cell types.12-03-2009
20090269847SELF-ASSEMBLING PEPTIDE AMPHIPHILES AND RELATED METHODS FOR GROWTH FACTOR DELIVERY - Amphiphilic peptide compounds comprising one or more epitope sequences for binding interaction with one or more corresponding growth factors, micellar assemblies of such compounds and related methods of use.10-29-2009
20130065304DIFFERENTIATION PROCESS OF MESENCHYMAL STEM CELLS AND THERAPEUTIC USE THEREOF - Process for inducing differentiation of mesenchymal stamina cells into neuroblasts and/or neurons that envisions the use of a differentiation solution consisting of retinoic acid and ethanol.03-14-2013
20130065303METHOD FOR INDUCING SPHEROID FORMATION OF ADIPOSE-DERIVED STEM CELLS AND TRANS-DIFFERENTIATION INTO NEURAL LINEAGE - The present invention relates to a basal medium for spheroid formation of adipose-derived stem cells, comprising a substrate; and a chitosan film faulted on a surface of the substrate, wherein the chitosan film comprises chitosan with 60-90% degree of deacetylation, and the chitosan film has a surface roughness defined by a height difference, measured between a highest position and a lowest position thereof, of 1-25 nm. In addition, the present invention further provides a method for inducing the spheroid trans-differentiating into neural lineages by using the basal medium of the present invention.03-14-2013
20110020932IN VITRO DIFFERENTIATION/INDUCTION OF LYMPHOCYTE FROM STEM CELL HAVING GENOTYPE PROVIDED AFTER GENE RECONSTITUTION - The present invention provides a production method of a functional differentiated cell having a post-rearrangement genotype of a particular antigen receptor gene, which includes culturing a stem cell having the genotype in a medium to give the differentiated cell derived from the stem cell. As the stem cell having the genotype, a stem cell (e.g., ES cell) established by transplantation of the nucleus of a cell having the genotype is preferable. As the differentiated cell, NKT cell is preferable.01-27-2011
20120115229EMBRYONIC STEM CELLS AND NEURAL PROGENITOR CELLS DERIVED THEREFROM - The present invention provides undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, and committed progenitor cells such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells and uses thereof. The invention also provides methods that generate in vitro and in vivo models of controlled differentiation of ES cells towards the neural lineage. The model, and the cells that are generated along the pathway of neural differentiation may be used for the study of the cellular and molecular biology of human neural development, for the discovery of genes, growth factors, and differentiation factors that play a role in neural differentiation and regeneration, for drug discovery and for the development of screening assays for teratogenic, toxic and neuroprotective effects.05-10-2012
20100035341Human Embryonic Stem Cell-Derived Connective Tissue Progenitors For Tissue Engineering - Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from embryonic stem cells and embryoid bodies are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.02-11-2010
20100087001ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.04-08-2010
20080305544Method of Producing Nerve Cell - An Object of the present invention is to provide a process for producing a nerve cell by inducing differentiation of an embryonic stem cell, a method for inducing differentiation of the embryonic stem cell into a nerve cell, a medium to be used in the production process or differentiation induction method, or a method for improving purity of the nerve cell obtained by inducing differentiation of the embryonic stem cell. The present invention provides a process for producing a nerve cell which is applicable to treatment of neurodegenerative disease or the like easily, selectively or inexpensively by inducing differentiation induction of an embryonic stem cell using vitamin B12-11-2008
20120238020Megakaryocyte and Platelet Production from Stem Cells - Methods for obtaining purified populations of megakaryocytes and platelets by ex vivo culture of stem cells are provided herein.09-20-2012
20120238019STEM CELL CULTURE MEDIA FOR MAINTAINING STEMNESS OR INDUCING DIFFERENTIATION OF STEM CELLS - The present invention provides a medium for maintaining stemness of stem cells comprising a protein kinase C inhibitor in a basal medium; and a method for culturing stem cells while maintaining stemness thereof, using the same. And also, the present invention provides a medium for inducing differentiation of stem cells comprising a protein kinase C activator in a basal medium; and a method for inducing differentiation of stem cells, using the same.09-20-2012
20080286867Method of Inducing Embryonic Stem Cells Into Pancreatic Cells - The present invention provided a simple three-step approach based on the combinational induction with activin A, all-trans retinoic acid and, optionally, other maturation factors which are able to induce embryonic stem cells to differentiate into insulin-producing cells. A kit used to induce embryonic stem cells to differentiate into insulin-producing cells was also provided.11-20-2008
20100159595METHOD OF GENERATING MYELINATING OLIGODENDROCYTES - A method of differentiating embryonic stem cells into oligodendroglial precursor cells and oligodendroglial cells by culturing a population of cells comprising a majority of cells that are characterized by a neural tube-like rosette morphology and are Pax6+/Sox1+ into a population of cells that are PDGFRα+.06-24-2010
20110300630METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.12-08-2011
20110281357Methods to cause differentiation of T-cells for use in cell therapy - A method resulting in differentiation of T-cells for use in cell therapy includes labeling the T-cells with a first array of antibodies specific for T-cell surface antigens; applying a universal cross-linking agent to the labeled T-cells with the first array of antibodies; labeling the T-cells with a second array of antibodies specific for T-cell surface antigens; and applying a universal cross-linking agent to the labeled T-cells with the second array of antibodies.11-17-2011
20110281356COMPOUNDS FOR STEM CELL DIFFERENTIATION - Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I:11-17-2011
20110281355Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.11-17-2011
20110143437METHOD FOR USING DIRECTING CELLS FOR SPECIFIC STEM/PROGENITOR CELL ACTIVATION AND DIFFERENTIATION - A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of antigen-presenting cells. Other applications are also described.06-16-2011
20110143436COMPOSITIONS AND METHODS FOR REPROGRAMMING EUKARYOTIC CELLS - The present invention relates to methods for changing the state of differentiation of a eukaryotic cell, the methods comprising introducing mRNA encoding one or more reprogramming factors into a cell and maintaining the cell under conditions wherein the cell is viable and the mRNA that is introduced into the cell is expressed in sufficient amount and for sufficient time to generate a cell that exhibits a changed state of differentiation compared to the cell into which the mRNA was introduced, and compositions therefor. For example, the present invention provides mRNA molecules and methods for their use to reprogram human somatic cells into pluripotent stem cells.06-16-2011
20110287540METHOD FOR CONTROLLING PROLIFERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS AND USE THEREOF - The present invention provides a method for controlling the proliferation and differentiation of cord blood-derived hematopoietic stem cells with excellent safety when proliferating them by culturing. The hematopoietic stem cells are inoculated into a medium containing a sonicated liquid component of cord blood. The proliferation and differentiation of the cord blood hematopoietic stem cells can be inhibited in the presence of the sonicated liquid component of cord blood. On the contrary, the proliferation of cord blood hematopoietic stem cells can be accelerated by inoculating the hematopoietic stem cells into a medium containing a non-sonicated liquid component of cord blood. Thus, according to the present invention, by using serum derived from cord blood, it is possible to regulate the inhibition of the proliferation and differentiation of cord blood hematopoietic stem cells and the acceleration of the proliferation of the same as desired.11-24-2011
20110287538METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR - An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.11-24-2011
20110287539Optimized Methods for Differentiation of Cells into Cells With Hepatocyte and Hepatocyte Progenitor Phenotypes, Cells Produced by the Methods, and Methods of Using the Cells - The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express hepatocyte phenotypes and hepatocyte progenitor phenotypes. More particularly, the invention relates to methods for culturing cells so that the cells are induced to differentiate into cells that express a definitive endodermal phenotype, a liver-committed endodermal phenotype, a hepatoblast phenotype, and hepatocyte phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.11-24-2011
20100112691Stem Cell Aggregate Suspension Compositions and Methods of Differentiation Thereof - The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.05-06-2010
20100105137METHOD FOR INDUCTION/DIFFERENTIATION INTO PHOTORECEPTOR CELL - The present invention provides a method of producing primate retinal progenitor cells, comprising culturing primate embryonic stem cells as suspended aggregates in a serum-free medium, and obtaining retinal progenitor cells from the culture. The present invention further provides a method of producing photoreceptor precursor cells, comprising culturing isolated retinal progenitor cells differentiated from embryonic stem cells, under adhesive conditions, in the presence of a gamma secretase inhibitor, and obtaining a photoreceptor precursor from the culture.04-29-2010
20100112693Differentiation of Human Embryonic Stem Cells - The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependant kinase inhibitor to cause an increase in expression of MAFA.05-06-2010
20100267141CHEMICAL APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS - The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.10-21-2010
20120034694CELL CULTURE SUPPORT AND CELL CULTURE METHOD - The present invention relates to a cell culture support for culturing mesenchymal stem cells, which includes en upper surface including a plurality of wells, in which the upper surface has a root mean square roughness Rq of 100 to 280 nm and a linear density of 1.6 to 10 per 1 μm length.02-09-2012
20100081199Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors - A method for efficient generation of neutrophils, eosinophils, macrophages, osteoclasts, dendritic cells an Langerhans cells from human embryonic stem cells is disclosed.04-01-2010
20120107934Human Late Stage Motor Neuron Progenitor Cells and Methods of Making and Using Same - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells.05-03-2012
20130071930POLYESTERS, METHODS OF MAKING POLYESTERS AND USES THEREFOR - Polyester compositions and functionalized polyester compositions are provided along with methods of making the compositions as well as methods of using the compositions, for example as a tissue engineering bioscaffold and as a drug-delivery vehicle.03-21-2013
20100081200FORMULATIONS AND METHODS FOR CULTURING STEM CELLS - The present invention relates to a serum replacement formulation and to a culture medium suitable for the derivation, maintenance and differentiation of stem cells.04-01-2010
20100093090METHOD AND KIT FOR EFFICIENT REPROGRAMMING OF SOMATIC CELLS - The present invention relates to method or kit for efficient reprogramming of somatic cells.04-15-2010
20130217125CULTURE METHOD - The invention provides methods of culturing cells, particularly maintaining the differentiation potential of a population of cells with differentiation potential. The methods involve contacting cells with an inhibitor of miRNA-181a* and/or incubation in a serum-free medium. A serum-free medium is also provided. Also provided are progeny stem cells, methods of obtaining them, and uses thereof.08-22-2013
20110201114Manufacturing Method of Immune Killer Cells - The present invention relates to a manufacturing method of immune killer cells characterized in that an immune killer cell is induced in a culture medium containing concanavalin A (ConA), and the immune killer cell is maintained or expanded in a culture procedure. Antibody proteins are not used as a stimulant in the culture process to avoid the risk of being infected by zoonotic diseases and effectively increase the number and specific release of the immune killer cells.08-18-2011
20110201113Ex Vivo Progenitor and Stem Cell Expansion and Differentiation for Use in the Treatment of Disease of the Nervous System - The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders,08-18-2011
20120295351METHOD FOR CLONING PLURIPOTENT STEM CELLS - Embodied herein are methods of reprogramming somatic cells or tissue stem cells to a more multipotent state or even a pluripotent state, the methods do not involve gene transfer of master transcription factor genes/proteins. The methods are also useful for rapid and efficient cloning of induced pluripotent stem cells after gene transfer of master transcription factor genes/proteins.11-22-2012
20090170198Differentiation of human embryonic stem cells - The present invention provides methods to promote the differentiation of pluripotent stem cells and the products related to or resulting from such methods. In particular, the present invention provides an improved method for the formation of pancreatic hormone expressing cells and pancreatic hormone secreting cells. In addition, the present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer and the products related to or resulting from such methods. The present invention also provides methods to promote glucose-stimulated insulin secretion in insulin-producing cells derived from pluripotent stem cells.07-02-2009
20090286317MODULAR CULTURE SYSTEM FOR MAINTENANCE, DIFFERENTIATION AND PROLIFERATION OF CELLS - The invention provides a culture system, which combines a device for undifferentiated proliferation of the cells with a device for cell differentiation and proliferation. Aspects of the invention include a modular culture system, a kit and an associated method for combining undifferentiated proliferation of cells with differentiation and proliferation of cells in a single, integrated device. The culture system has a first compartment comprising a plurality of miniaturized culture cavities that are sealed on one end by a surface that may be perforated, and a second compartment which defines one or more, larger culture chambers, and wherein said first and second compartment can be sterilely connected and living cell material can be transferred directly and in a controlled manner from the first compartment into the second compartment.11-19-2009
20090104697Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells - An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.04-23-2009
20090170197Nucleic Acid-Mediated Treatment of Diseases or Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor (VEGF-R) - The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nucleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.07-02-2009
20080305546Method for cultivating tendon cells from pluripotent cells of mesenchymal origin - A method for cultivating tendon cells from non-embryonic pluripotent cells of mesenchymal origin is described, wherein the isolated cells are cultivated in a culture medium under standard culture conditions in a culture vessel. In order to increase the collagen secretion, it is proposed that before their complete confluence, the cells are on the one hand further cultivated in a culture medium mixed with ascorbic acid and/or ascorbic acid-2-phosphate in a concentration of 25 to 75 μg/ml and on the other hand, subjected to hyperosmolar treatment in a culture medium whose osmolarity is adjusted to 350 to 500 mosmol/l.12-11-2008
20080305545Shape memory thermoplastics and polymer networks for tissue engineering - Methods and compositions are described herein for reconstruction of different functional tissues. Dissociated cells, differentiated cells, adult mesenchymal stem cells or embryonic stem cells are seeded on a scaffold. The scaffold will consist of a biocompatible, biodegradable shape memory (“SM”) polymers. In addition bioactive substances may be incorporated in the scaffold. Thermoplastic as well as thermoset materials with SM-effect can be used. The shape memory effect will be applied as an interactive link between the cells and the used polymeric scaffold. The degradation kinetics as well as shape memory transition temperature will be tailored by adjusting to monomer ratios of the co-oligomers. The shape memory effect will be used to create a degradation or release of bioactive substances on demand, induce forces on seeded cells or induce proliferation and differentiation of cells.12-11-2008
20100273259SUBSTRATES AND METHODS FOR CULTURING STEM CELLS - The present disclosure provides a device and a cell culture system comprising a substrate that generates significant chemical ion signatures adapted for culturing stem cells. This disclosure further provides unique surface properties, such as surface wettability, along with defined polymer microspot environments in an array, for effectively supporting the propagation and differentiation of human pluripotent stem cells in vitro. Methods of culturing, maintenance, differentiating stem cells as well as reprogramming somatic cells into stem cells using the device and the cell culture system with the suitable substrates, along with suitable culture media, are also provided.10-28-2010
20090029470PROCESS AND CULTURING UNIT FOR CULTURING BIOLOGICAL CELLS - A targeted cultivation phase adjustment is provided in a process for the cultivation of cells in which biological cells are cultivated on at least one boundary surface between different, non-solid cultivation phases so that pre-determined cultivation conditions are given. A cultivation apparatus (01-29-2009
20090298179Methods For Treating Degenerative Diseases/Injuries - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.12-03-2009
20090035855THREE-DIMENSIONAL RECONSTITUTED EXTRACELLULAR MATRICES AS SCAFFOLDS FOR TISSUE ENGINEERING - A biomaterial scaffold comprising: a) reconstituted extracellular matrix; and b) polyelectrolyte complex fibers; wherein the matrix and the fibers are functionally associated.02-05-2009
20090004736GENERATION OF NEURAL STEM CELLS UNDIFFERENTIATED HUMAN EMBRYONIC STEM CELLS - The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.01-01-2009
20090325294SINGLE PLURIPOTENT STEM CELL CULTURE - The present invention relates to the field of pluripotent stem cell culture and methods facilitate pluripotent stem cell culture at industrial levels.12-31-2009
20090325295IN-VITRO MECHANICAL LOADING OF MUSCULOSKELETAL TISSUES - Musculoskeletal tissues produced in vitro are optimized in response to an externally applied mechanical load. The load applied may vary from tissue to tissue, depending upon the response desired, and may include intermittent axial, torsional, and bending loads to produce cortical structures. Compression alone is preferably applied to produce cancellous bone. A method according to the invention for culturing bone in vitro comprises: providing a culture vessel providing a scaffold material, supporting the scaffold material within the tissue culture vessel so as to be exposed to a tissue culture medium, and exerting a force on the scaffold material during growth of a bone construct (a cultured bone growth) around the scaffold material. Applicable apparatus preferably includes a culture vessel, holders for holding a scaffold within the tissue culture vessel, means for introducing a tissue culture medium to the tissue culture vessel, and an actuator adapted to apply a force to developing bone during the in vitro culture of the tissue, whether bone, cartilage, ligament, or composites thereof.12-31-2009
20090081791INTRACELLULAR DELIVERY OF SMALL MOLECULES, PROTEINS, AND NUCLEIC ACIDS - An amino acid sequence Arg-Lys-Met-Leu-Lys-Ser-Thr-Arg-Arg-Gln-Arg-Arg (SEQ ID NO:1) functions as a protein transduction domain (PTD) and is capable of delivering small molecules, proteins, and nucleic acids to an intracellular compartment of a cell. An amino terminal lysine linker improves the efficiency of the PTD. A nuclear localization signal can be used to target the PTD to a cell's nucleus. The PTD can be used in PTD-cargo moiety complexes that can reversibly immortalize cells and increase cell viability in culture.03-26-2009
20090162934MULTIPLE MESODERMAL LINEAGE DIFFERENTIATION POTENTIALS FOR ADIPOSE TISSUE-DERIVED STROMAL CELLS AND USES THEREOF - The invention relates to methods and compositions for the differentiation of stromal cells from adipose tissue into hematopoietic supporting stromal cells and myocytes of both the skeletal and smooth muscle type. The cells produced by the methods are useful in providing a source of fully differentiated and functional cells for research, transplantation and development of tissue engineering products for the treatment of human diseases and traumatic tissue injury repair.06-25-2009
20120142102ISOLATION OF HUMAN UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS - Human umbilical cord blood (UCB) contains mesenchymal stem cells (MSCs) that have higher multipotentiality than adult marrow-derived MSCs. However, it has been difficult to obtain these cells because the frequency of MSCs in UCB is extremely rare (0.4-30 out of 1×1006-07-2012
20100159596SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION - Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof:06-24-2010
20090239300SEPARATING MATERIAL AND METHOD FOR COLLECTING CELL OR THE LIKE USING THE SAME - The present invention provides a novel material useful for selectively isolating a cell such as monocyte and the like or a protein from a body fluid and a production method thereof, a physiological material using the material and an isolation material using the physiological material, as well as a method of harvesting a cell such as monocyte and the like using the isolation material, a method of harvesting a protein and a method of preparing a dendritic cell.09-24-2009
20090117651Nucleoside compounds and methods of use thereof - The present invention provides methods of utilizing a nucleoside derivative having the chemical formula of Formula (I) to downregulate expression of an anti-apoptotic protein such as survivin in a cell, induce apoptosis in a cell, inhibit angiogenesis in a cell, inhibit binding of p53 to DNA in a cell, inhibit phosphorylation of Akt in a cell and inhibit HIV transcription in a cell, by administering to the cell or tissue an amount of a compound of Formula (I) sufficient to achieve the desired activity. Formula (I): wherein the substituents R05-07-2009
20090117652USE OF CXCL6 CHEMOKINE IN THE PREVENTION OR REPAIR OF CARTILAGE DEFECTS - The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.05-07-2009
20090221072COMPOSITIONS AND METHODS FOR MODULATING CELL DIFFERENTIATION - Compositions and methods are described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I to inhibit hematopoiesis and to induce differentiation of neuroblastoma cells and neuronal stem cells.09-03-2009
20090239301USE OF VINCA ALKALOIDS AND SALTS THEREOF - An agent containing a vinca alkaloid or its pharmacologically acceptable salt as an active ingredient can induce insulin production and/or secretion of non-neoplastic cells derived from the pancreas.09-24-2009
20090246871CONTAINER FOR GERM LAYER FORMATION AND METHOD OF FORMING GERM LAYER - The invention relates to a vessel for embryoid formation used for forming embryoid bodies from ES cells easily without complicated technique, and to a method for forming embryoid bodies easily and efficiently using the vessel. The method includes the steps of (A) providing a vessel for embryoid formation having a coating layer formed from a compound having a particular PC-like group on a vessel surface defining a region for floating culture of ES cells, and (B) floating culturing ES cells in the vessel to form embryoid bodies.10-01-2009
20090258423Cell cycle regulation and differentiation - The present invention provides compositions and methods for regulating neural cell proliferation or differentiation. The present invention also provides methods for selecting for bioactive agents effective in regulating proliferation or differentiation.10-15-2009
20080318316Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same - A method is provided for controlling the survival, proliferation, and/or differentiation of hepatic progenitors in vitro by using specific types of mesenchymal feeder cells or one of more of the paracrine signals produced by those feeders.12-25-2008
20100015709Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity - Provided are methods for the selection and regulation of the mechanical properties of 2D or 3D biocompatible substrates or tissue microenvironments as a technique to regulate in vitro differentiation, cell shape and/or lineage commitment of anchorage-dependent cells, such as mesenchymal stem cells into, e.g., neurogenic-, myogenic-, and osteogenic-type cells. Substrate mechanical properties include elasticity, tension, adhesion, and myosin-based contractile mechanisms. Inhibitors can be introduced to further regulate differentiation.01-21-2010
20100015711Differentiation of Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.01-21-2010
20100178700NOVEL THYMIC CELLULAR POPULATIONS AND USES THEREOF - The present invention relates generally to novel thymic cellular populations and, more particularly, to novel thymic epithelial cellular populations. Most particular, the present invention is directed to novel thymic epithelial progenitor cell populations. The cellular populations of the present invention are useful in a wide range of clinical and research settings including, inter alia, the in vitro or in vivo generation of thymic epithelial cell populations and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the design of in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which thymic epithelial cells may be exposed. In another aspect, the present invention is directed to a method of identifying thymic epithelial cellular subpopulations and, more particularly, thymic epithelial progenitors by screening for the co-expression of markers including MHC Class II, UEA1 and Ly51. This method is useful in a range of applications including, but not limited to, assessing or monitoring for the presence of thymic epithelial cell populations and/or facilitating the isolation of or enrichment for these cellular populations of use in a range of research and clinical applications.07-15-2010
20120196365Differentiation of Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.08-02-2012
20100184217STEM CELL LINES, THEIR APPLICATION AND CULTURE METHODS - New lines of stem cells from the growing antlers of deer (Cervidae) and the application of said cells in the reconstruction of connective tissue, preferentially bone, cartilage or adipose tissue, in humans and animals; as well as a method of culturing them and the application of tissues from growing deer antlers in the production of the MIC-1 stable stem cell line.07-22-2010
20080213892SELF-RENEWAL OF NEURAL STEM CELLS IS PROMOTED BY WNT PROTEINS - Mammalian neural progenitor or stem cells are expanded in vitro by culture in the presence of one or more wnt polypeptides. The expanded cells substantially maintain their original phenotype including the ability to give rise to multiple types of differentiated cells.09-04-2008
20080213891RNAi Agents Comprising Universal Nucleobases - One aspect of the present invention relates to an oligonucleotide agent comprising at least one universal nucleobase. In certain embodiments, the universal nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the universal nucleobase is difluorotolyl. In certain embodiments, the oligonucleotide is double-stranded. In certain embodiments, the oligonucleotide is single-stranded. Another aspect of the present invention relates to a method of altering the expression level of a target in the presence of target sequence polymorphism. In a preferred embodiment, the oligonucleotide agent alters the expression of different alleles of a gene. In another preferred embodiment, the oligonucleotide agent alters the expression level of two or more genes. In another embodiment, the oligonucleotide agent alters the expression level of a viral gene from different strains of the virus. In another embodiment, the oligonucleotide agent alters the expression level of genes from different species.09-04-2008
20110059526REPROGRAMMING A CELL BY INDUCING A PLURIPOTENT GENE THROUGH USE OF AN HDAC MODULATOR - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC with an HDAC inhibitor and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In still another embodiment, the invention relates to a method for reprogramming comprising exposing a cell to more than one agent to inhibit more than ore type of regulatory protein. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into various differentiated cell types03-10-2011
20100240130Differentiation and Enrichment of Islet-like Cells from Human Pluripotent Stem Cells - Methods for differentiating human pluripotent stem cells into islet-like cells are provided. In certain embodiments, the methods utilize sequential culturing of the human pluripotent stem cells with certain factors to produce islet-like cells. In certain embodiments, the population of cells produced by the methods is further enriched for islet-like cells.09-23-2010
20100136688METHOD OF DIFFERENTIATING MAMMALIAN PROGENITOR CELLS INTO INSULIN PRODUCING PANCREATIC ISLET CELLS - The invention relates to methods for differentiating progenitor cells into insulin producing pancreatic islet cells and compositions and methods for using such cells.06-03-2010
20120142103METHOD FOR INDUCING DIFFERENTIATION INTO EPITHELIAL PROGENITOR CELL/STEM CELL POPULATION AND CORNEAL EPITHELIAL CELL POPULATION FROM INDUCED PLURIPOTENT STEM CELLS - The present invention relates to: a method for inducing differentiation into an epithelial progenitor cell/stem cell population or a corneal epithelial cell population by culturing, under particular conditions, induced pluripotent stem cells induced from mammalian somatic cells or undifferentiated stem cells; an epithelial progenitor cell/stem cell population or a corneal epithelial cell population obtained by the method; and a cell preparation for the treatment of epithelial disease and a cell sheet, which are prepared using these cell populations.06-07-2012
20090186411Cell culture apparatus, method for producing the apparatus and cell culture method - The invention relates to a cell culture apparatus for cells, characterized by a surface composed of an unstructured elastomer. It is thus possible for cells to be cultured under close to natural conditions in relation to their environmental elasticity. A method for producing an apparatus according to the invention is disclosed, as is a cell culture method using such an apparatus.07-23-2009
20100297763CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS - Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.11-25-2010
20100261276Method For The Preparation Of Dermal Papilla Tissue Employing Mesenchymal Stem Cells - A method for the preparation of dermal papilla tissue comprising the step of culturing mesenchymal stem cells in a medium having a specific composition is provided. The method makes it possible to form in vitro a quantity of dermal papilla tissues having hair follicle inducting ability and, accordingly, it can be effectively used for the treatment of alopecia through cell transplantation.10-14-2010
20130143322METHOD FOR CONTROLLING PROLIFERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS AND USE THEREOF - The present invention provides a method for controlling the proliferation and differentiation of cord blood-derived hematopoietic stem cells with excellent safety when proliferating them by culturing. The hematopoietic stem cells are inoculated into a medium containing a sonicated liquid component of cord blood. The proliferation and differentiation of the cord blood hematopoietic stem cells can be inhibited in the presence of the sonicated liquid component of cord blood. On the contrary, the proliferation of cord blood hematopoietic stem cells can be accelerated by inoculating the hematopoietic stem cells into a medium containing a non-sonicated liquid component of cord blood. Thus, according to the present invention, by using serum derived from cord blood, it is possible to regulate the inhibition of the proliferation and differentiation of cord blood hematopoietic stem cells and the acceleration of the proliferation of the same as desired.06-06-2013
20130164847USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS - The present invention pertains to methods of using protein tyrosine kinase (PTK) inhibitors for inducing cell differentiation of mesenchymal stem cells into cardiac cells, and a pharmaceutical composition comprising the differentiated cardiac cells thereof to treat heart diseases. The transplantation of mesenchymal stem cells to the heart provides immunological and functional improvements, but does not provide electrical stability. However, the mesenchymal stem cells treated with PTK inhibitors are induced to be differentiated into cardiogenic cells to provide electrical stability as the electromechanical integration with host heart tissue is improved, and it is thus possible to effectively treat cardiac diseases such as cardiac infarction, cardiac insufficiency, arrhythmia and the like.06-27-2013
20110008892METHODS OF TISSUE GENERATION AND TISSUE ENGINEERED COMPOSITIONS - Provided are methods and compositions for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue, and treating renal failure. Disclosed are methods of using an active epithelial growth factor having the capability of effectuating induction of growth and morphogenesis is cells.01-13-2011
20110129922METHOD FOR INDUCING DIFFERENTIATION INTO CARDIOMYOCYTES USING G-CSF - A method for inducing differentiation of ES cells into cardiomyocytes, which comprises contacting the ES cells with an agonist for G-CSF receptor.06-02-2011
20110212523DIFFERENTIATION-INDUCING CULTURE MEDIUM ADDITIVE AND USE THEREOF - Provided is a differentiation-inducing culture medium additive for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition, and a use of the differentiation-inducing culture medium additive. The differentiation-inducing culture medium additive of the present invention for inducing differentiation of a stem cell under a serum-free condition at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and β-glycerophosphate. The differentiation-inducing culture medium additive of the present invention does not require ascorbic acid 2-phosphate and ITS, which are normally essential for bone differentiation. Further, bone differentiation can be promoted by adding phospholipid.09-01-2011
20100227404WATER EXTRACT OF ANTRODIA CAMPHORATA FOR IMMUNOSTIMULATORY EFFECT AND PREPARATION METHOD THEREOF - A preparation method for a water extract of the fruiting body of 09-09-2010
20090124009ANTISENSE MODULATION OF PTP1B EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.05-14-2009
20100055789METHOD AND APPARATUS FOR THE STIMULATION OF HAIR GROWTH - A method for activating or inhibiting the differentiation of stem cells including exposing the stem cells to a source of narrowband multi chromatic electromagnetic radiation under conditions effective to activate or inhibit cell differentiation.03-04-2010
20090215175MODULATION OF THE POLIOVIRUS RECEPTOR FUNCTION - The present invention relates to the identification, the isolation and the use of molecules interfering with the function (s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful for identifying and isolating molecules, which have the capacity to modulate PVR mediated adhesion or invasion potential of cells.08-27-2009
20100068810METHODS AND COMPOSITIONS FOR GROWTH OF EMBRYONIC STEM CELLS - The present invention provides methods and compositions for establishing and maintaining growth of undifferentiated stem cells. In particular, the present invention provides synthetic growth matrices for stem cells, wherein said cells are capable of going through multiple passages while remaining in an undifferentiated state.03-18-2010
20110151561DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to increase the expression of NGN3 and NKX6.1 in populations of cells expressing markers characteristic of the pancreatic endocrine lineage.06-23-2011
20110151560DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.06-23-2011
20110033931DE-DIFFERENTIATION OF HUMAN CELLS - Methods of de-differentiating somatic cells to an embryonic stem cell state comprising direct delivery of a protein into the somatic cell, wherein the protein effects de-differentiation of the somatic cell to an embryonic stem cell phenotype.02-10-2011
20100297765METHOD FOR PRODUCING LANGERHANS CELLS OR INTERSTITIAL DENDRITIC CELLS OR BOTH FROM CD14+ MONOCYTES - The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells or both from CD1411-25-2010
20100304486METHODS OF GENERATING EMBRYOID BODIES AND USES OF SAME - Methods of generating embryoid bodies (EBs) by culturing embryonic stem cells (ESCs) under static conditions followed by culturing the cells under dynamic conditions using e.g., a Glass Bulb-shaped Impeller (GBI) or shaking a culture vessel are provided. Also provided are methods of generating expanded and/or differentiated cells from the EBs of the invention and methods of using same for treating disorders requiring cell replacement therapy.12-02-2010
20100297764USE OF A HYDROGEL FOR THE CULTURE OF CHONDROCYTES - The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.11-25-2010
20110250686NOVEL HEPATOCYTE-LIKE CELLS AND HEPATOBLAST-LIKE CELLS DERIVED FROM hBS CELLS - The present invention relates to a novel hepatocyte-like cell population derived from hBS cells and to the potential use of such heopatocyte-like cells in e.g. medical treatment, drug screening and toxicity testing. Furthermore, the invention relates to 5 hepatoblast-like cells that may have suitable characteristics so that they can be used for the same applications as the hepatocyte-like cells and that furthermore may be used in in vitro studies of hepatogenesis such as early hepatogenesis or hepatoregenerative disorders. Both the hepatocyte-like and the hepatoblast-like cells according to the invention express drug transporter and/or drug metabolising 10 characteristics either at the gene or protein expression level.10-13-2011
20110151562WHITE BLOOD CELL DIFFERENTIATION REAGENT AND METHOD - A reagent for four-part differentiation of white blood cells is provided. In one embodiment the reagent has an osmolality below 50 mOsm/kg H06-23-2011
20100003753Multivalent rna nanoparticles for delivery of active agents to a cell - A polyvalent multimeric complex formed from a plurality of chimeric pRNA molecules, each carrying at least one biologically active moiety, detectable label, or other heterologous component.01-07-2010
20100003754METHODS OF DIFFERENTIATING STEM CELLS - A method for at least partial differentiating stem cells and/or progenitor cells to at least one tissue type includes treating the stem cells and/or the progenitor cells with extracts which include active substances and/or components for differentiating stem cells and/or progenitor cells, and cultivating and differentiating the stem cells and/or the progenitor cells.01-07-2010
20110177597CELLULAR DIFFERENTIATION PROCESS AND ITS USE FOR BLOOD VESSEL BUILD-UP - A process of differentiation of stem cells through the use of specific oxygen concentrations, provided that the stem cells are not human embryonic stem cells, and seeded on a support, in an appropriate culture medium, wherein the differentiation leads to: 07-21-2011
20080254538Treatment of Neurological Deficits in the Striatum or Substanta Nigra Pars Compacta - The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.10-16-2008
20110027886METHOD OF INDUCING DIFFERENTIATION OF EMBRYONIC STEM CELLS INTO HEMANGIOBLAST - The present invention relates to a composition for inducing embryonic stem cell differentiation comprising a MEK/ERK (mitogen-activated protein kinase kinase/extracellular regulated kinase) signal transduction inhibitor and BMP (bone morphogenetic protein), and a method for inducing differentiation of embryonic stem cells into mesodermal cells using the same. Further, the mesodermal cells obtained by the above method are able to differentiate into various mesenchymal tissue cells. In particular, the present invention relates to a method for inducing differentiation into hemangioblast by culturing the mesodermal cells obtained by the above method in the presence of VEGF (vascular endothelial cell growth factor) and bFGF (basic fibroblast growth factor). The differentiated hemangioblasts can be further differentiated into vascular endothelial cells, vascular smooth muscle cells, and hematopoietic stem cells under various culture conditions.02-03-2011
20100285585METHOD FOR EXTRACELLULAR MATRIX MEDIATED DIFFERENTIATION AND PROLIFERATION OF STEM CELLS - There is provided a method of culturing a stem cell on extracellular matrix extracted from support cells and in a stem cell culture medium comprising medium conditioned by the support cells11-11-2010
20100285584ENGINEERED CELLULAR PATHWAYS FOR PROGRAMMED AUTOREGULATION OF DIFFERENTIATION - The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type. A quorum sensing systems that regulates the expression of cell fate regulators is introduced into mammalian host cells, such as stem cells. The quorum sensing systems generally comprises vectors that express the components of a bacterial quorum sensing pathway, including proteins which catalyze the synthesis of an autoinducer and a gene encoding a regulatory partner of the autoinducer, and vectors in which genes encoding cell fate regulators are operably linked to a promoter induced by the autoinducer/regulatory partner complex. The system can also comprise vectors in which genes encoding additional cell fate regulators are operably linked to a promoter that is induced by a factor synthesized in response to a first stage of differentiation, so that a second stage of differentiation is triggered.11-11-2010
20100285586METHOD OF PRODUCING A POPULATION OF CELLS - A method is provided for producing an in vitro or ex vivo method of producing a population of lineage committed haematopoietic progenitor, or mature haematopoietic cells, other than cells of the neutrophil lineage, which method comprises the steps of: (a) providing a population of cells comprising haematopoietic progenitor cells; and (b) culturing the population of cells in an animal cell culture medium comprising one or more cytokines that differentiate said progenitor cells into lineage committed haematopoietic progenitor and/or mature haematopoietic cells, under conditions of low oxidative stress, the culture medium being agitated when the cells are at a cell density at which oxygen transfer via the surface of the culture medium is insufficient for growth of the progenitor cells and the progeny thereof under static conditions, to produce a population of lineage committed haematopoietic progenitor, or mature haematopoietic cells, other than cells of the neutrophil lineage. The resulting population of cells can be used to increase the number of haematopoietic cells in a patient.11-11-2010
20100323443Composition and method for enabling proliferation of pluripotent stem cells - The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, that both maintain stem cells in vitro pluripotency and enable self-renewal. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or their functional domains, in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferated and maintained their pluripotency.12-23-2010
20100323444CULTURING AND DIFFERENTIATING NEURAL PRECURSOR CELLS - Systems and methods have been developed for large-scale propagation and differentiation of populations of neurons and glia from neural precursor cells derived from postnatal brain. Under culture conditions containing pituitary extract and mitogenic factors, cells derived from neural stem cells can be attached to a substrate, maintained and serially passaged in culture. Upon removal of mitogenic factors, clusters of neural progenitor cells can be induced that co-express markers of neural stem cells and immature neurons. Unlimited numbers of cells at characterized stages of neurogenesis can be produced. Upon maturation, neuronal cells extend processes and differentiate into mature neuronal phenotypes capable of generating action potentials.12-23-2010
20100330672HUMAN STEM CELLS ORIGINATING FROM HUMAN AMNIOTIC MESENCHYMAL CELL LAYER - Neural stem cells which can be provided stably and which are free from the problem of compatibility in transplantation are disclosed. The stem cells are separated from human amniotic mesenchymal cell layer and express vimentin, nestin and BrdU which are markers of neural stem cells. The stem cells can also be differentiated to cells expressing alkaline phosphatase, that is, osteocytes, and to cells expressing collagen type II, that is, chondrocytes.12-30-2010
20100221833PROCESS FOR DIFFERENTIATION OF VASCULAR ENDOTHELIAL PROGENITOR CELLS FROM EMBRYOID BODIES DERIVED FROM EMBRYONIC STEM CELLS USING HYPOXIC MEDIA CONDITION - The present invention provides a process for differentiation of vascular endothelial progenitor cells from embryoid bodies derived from embryonic stem cells, the process comprising: (a) treating a culture medium comprising embryoid bodies derived from embryonic stem cells such that the concentration of oxygen dissolved in the culture medium is in the range of about 1 ppm to about 5 ppm; (b) culturing the culture medium prepared in step (a) in an incubator in which the oxygen (O09-02-2010
20100197019Method for Cultivation of Hair Follicular Dermal Sheath Cells - A method for culture of hair follicular dermal sheath cells or precursor cells thereof which are potent cellular materials for such as hair regeneration by cell transplantation is provided. That is, by performing culture in an animal cell culture medium supplemented with platelet-derived growth factor AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), hair follicular dermal sheath cells are proliferated while sustaining their function, or hair follicular dermal sheath precursor cells are differentiated into dermal sheath cells and proliferated.08-05-2010
20090176306METHOD OF INDUCING DIFFERENTIATION FROM VISCERAL PREADIPOCYTE TO VISCERAL ADIPOCYTE - The invention provides a method of inducing differentiation of a visceral preadipocyte and a method of culturing a visceral adipocyte comprising culturing the cell in a medium containing serum free of heparin-adsorbable components. The invention also provides for the removal of heparin-adsorbable components by, for example, applying serum to a heparin affinity column thereby adsorbing the heparin-adsorbable component to heparin. A visceral adipocyte cultured by the method of the present invention is useful in a study of differentiation, growth and metabolism of an adipocyte, elucidation of the mechanism of development and progress of diseases such as diabetes, hyperlipemia, hypertension and arteriosclerosis, and development of a drug for preventing and treating such a disease.07-09-2009
20090176307Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.07-09-2009
20090197334METHODS OF CULTURING EMBRYONIC STEM CELLS AND CONTROLLED DIFFERENTIATION - The present invention provides a preparation of undifferentiated embryonic stem (ES) cells sustainable for a prolonged period in an undifferentiated state which will undergo stem cell renewal or somatic differentiation. Preferably the cells are capable of somatic differentiation in vitro and are inclined to differentiate away from an extraembryonic lineage. The present invention also provides method of culturing embryonic stem (ES) cells to improve stem cell maintenance and persistence in culture. The method also provides a culture of ES cells prepared by the method as well as differentiated cells derived from the embryonic cells resulting from directed differentiation procedures provided by the present invention.08-06-2009
20090197333METHOD FOR PRODUCTION OF BIOLOGICAL ORGANIC MATERIAL AND CULTURE VESSEL - Disclosed is a method for producing a biological organic material in a liquid droplet comprising a culture medium composed of specified ingredient. The method comprises the steps of: providing a substantially spherical liquid droplet on a substrate in an unadhered state, the substrate preferably having such a water-repellent surface that the water contact angle becomes 150° or greater; and culturing a biological organic material in the liquid droplet.08-06-2009
20100190251Method for the differentiation of human adult stem cells into insulin-secreting cells - Disclosed is a method for differentiating human adult stem cells into insulin-secreting cells. Human adult stem cells, isolated from the subcutaneous adipose tissues around the eyes, are induced to differentiate into insulin-secreting cells in a medium in the presence of cytokines and growth factors including B27 supplement, fibroblast growth factor-2, epidermal growth factor, nicotinamide, glucagon-like peptide-1, activin A, insulin-like growth factor, betacellulin, etc., with a glucose shift from a high concentration to a low concentration. Having the ability to producing insulin and C-peptide at high levels, the insulin-secreting cells can be excellent curatives for type 1 diabetes mellitus.07-29-2010
20100022003Therapeutic cell medicine comprising skin tissue derived stem cell - Provided is a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs). More specifically, the present invention provides a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs) isolated from skin tissues and a method for differentiation of the skin-derived progenitor cells (SPCs) into neural cell lineages. The cell therapeutic agent in accordance with the present invention is therapeutically effective for the treatment of the neurological disorders and diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS) caused by neural injury, and neurological deficits due to cerebral apoplexy, ischemia and spinal cord injury. Further, the present invention enables transplantation of autologous cells to thereby minimize adverse side effects.01-28-2010
20110070646Biomimetic Cell Scaffolds - This invention relates to biomimetic implants containing mammalian cells which are induced by their environment to produce gradients of diffusible factors. This may be useful in eliciting a physiological pro-angiogenic response which stimulates angiogenesis and revascularisation in tissue adjacent the implant, for example in therapeutic applications in which increased angiogenesis and/or vasculogenesis is required. This may also be useful in providing biomimetic mammalian cell niches for cell culture and differentiation.03-24-2011
20110070645COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PDX1+ PANCREATIC CELLS - Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described.03-24-2011
20100261277METHODS AND COMPOSITIONS FOR ENHANCED DIFFERENTIATION FROM EMBRYONIC STEM CELLS - The invention provides methods for differentiating pluripotent stem cells such as ES cells with improved progenitor and differentiated cell yield using low oxygen conditions and optionally in the absence of exogenously added differentiation factors.10-14-2010
20090246870DE-DIFFERENTIATION OF ASTROCYTES INTO NEURAL STEM CELL USING NANOG - Disclosed are a composition and a method for inducing the de-differentiation of astrocytes into neural stem cells using Nanog. The de-differentiated neural stem cells have the ability to differentiate into astrocytes, neurons, or oligodendrocytes.10-01-2009
20090253203Reprogramming a Cell by Inducing a Pluripotent Gene Through Use of a Small Molecule Modulator - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises exposing a cell to a small molecule modulator that induces the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the invention relates to a reprogrammed cell and an enriched population of reprogrammed cells that can have characteristics of an ES-like cell can be re- or trans-differentiated into various differentiated cell types.10-08-2009
20110306133CULTURE MEDIUM AND METHOD FOR INDUCING DIFFERENTIATION INTO ADIPOCYTES - Disclosed are a culture medium, an additive, and a method for efficiently inducing the differentiation of mammalian somatic stem cells into cells having the characteristics of adipocytes under conditions of serum-free or low-serum culture medium. The culture medium for inducing the differentiation of mammalian somatic stem cells into adipocytes comprises a basal medium for culturing mammalian cells, an agent for inducing the differentiation of mammalian somatic stem cells into adipocytes, biotin, a ligand for endothelial cell differentiation gene (Edg) family receptors, vitamin C, and HEPES, which culture medium is serum-free or contains a low concentration of serum.12-15-2011
20110306132CULTURE MEDIUM AND METHOD FOR INDUCING DIFFERENTIATION INTO BONE CELLS - Disclosed are a culture medium, an additive, and a method for efficiently inducing the differentiation of mammalian somatic stem cells into cells having the characteristics of bone cells under conditions of serum-free or low-serum culture medium. The culture medium for inducing the differentiation of mammalian somatic stem cells into bone cells comprises a basal medium for culturing mammalian cells, an agent for inducing the differentiation of mammalian somatic stem cells into bone cells, a ligand for endothelial cell differentiation gene (Edg) family receptors and selenium, which culture medium is serum-free or contains a low concentration of serum. The method for inducing differentiation from somatic stem cells into bone cells comprises culturing the somatic stem cells that can differentiate into bone cells in the above-described culture medium.12-15-2011
20110003387METHOD OF PRODUCING ERYTHROCYTES WITHOUT FEEDER CELLS - Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.01-06-2011
20090047739Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells - This invention provides a new procedure for generating cardiomyocyte lineage cells from embryonic stem cells for use in regenerative medicine. Differentiating by way of embryoid body formation or in serum is no longer required. Instead, the stem cells are plated onto a solid substrate, and differentiated in the presence of select factors and morphogens. After enrichment for cells with the appropriate phenotype, the cells are allowed to cluster into Cardiac Bodies™, which are remarkably homogeneous and suitable for the treatment of heart disease.02-19-2009
20110014704ISOLATION OF MULTI-LINEAGE STEM CELLS - The present application discloses a method of manipulating a biological sample of cells, which includes multi-lineage stem cells, progenitor cells, other marrow stromal cells: allowing the sample of cells to settle in a container; transferring supernatant from the container to another container; and isolating cells from the supernatant, which has comparatively lower density in the sample.01-20-2011
20120301962VITRONECTIN-DERIVED CELL CULTURE SUBSTRATE AND USES THEREOF - Vitronectin-derived cell culture substrates and methods of using the same for culturing pluripotent stem cells are presented.11-29-2012
20100015710Methods and Compositions for Isolating, Maintaining and Serially Expanding Human Mesenchymal Stem Cells - Compositions and methods for isolating and expanding human mesenchymal stem/progenitor cells through multiple passages in defined serum-free environments are provided. The culture media compositions includes a basal medium supplemented with a nutrient mixture such as Ham's F12 nutrient mixture, glutamine, buffer solutions such as sodium bicarbonate and hepes, serum albumin, a lipid mixture, insulin, transferrin, putrescine, progesterone, fetuin, hydrocortisone, ascorbic acid or its analogues such as ascorbic acid-2-phosphate, fibroblast growth factor and transforming growth factor β, and are free of serum or other undefined serum substitutes such as platelet lysate. Methods employing these compositions and protein-coated surfaces for the isolation of mesenchymal stem/progenitor cells from human bone marrow and other tissues such as adipose tissue are also provided. Finally, methods are also provided for serially expanding these cells through multiple passages without losing mesenchymal stem cell-specific proliferative, phenotypical and differentiation characteristics.01-21-2010
20110111502ELIMINATION OF IMMUNE RESPONSES TO VIRAL VECTORS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.05-12-2011
20090053809Retina-Specific Cells Differentiated In Vitro from Bone Marrow Stem Cells, the Production Thereof and Their Use - The invention relates to the production of retina-specific cells from human adult bone marrow stem cells by culturing bone marrow stem cells in the presence of a differentiation medium. The invention also relates to retina-specific cells and to the use of these cells for treating diseases associated with acquired or congenital dysfunction of the retinal pigment epithelium, cells of adjacent structures of the entire retina and of the choroid coat as well as of other eye tissue.02-26-2009
20100184218Isolation and Culture-Expansion Methods of Mesenchymal Stem/Progenitor Cells From Umbilical Cord Blood, And Differentiation Method of Umbilical Cord Blood-Derived Meschymal Stem/Progenitor Cells Into Various Mesenchymal Tissues - There is provided a method for the isolation and cultivation of mesenchymal stem/progenitor cells from umbilical cord blood, and also to a method for the differentiation of the umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues. The method include overlaying umbilical cord blood onto Ficoll-Hypaque solution; centrifuging the umbilical cord blood on the Ficoll-Hypaque solution to obtain a mononuclear cell layer; reacting cells obtained by monolayer culture of the mononuclear cells with antibodies to mesenchymal stem/progenitor cell-specific antigens for a predetermined period of incubation time; isolating only cells bound to their corresponding antibodies using a cell sorter; and cultivating the isolated cells, thereby obtaining mesenchymal stem/progenitor cells with high purity and excellent viability.07-22-2010
20110097799CARDIOMYOCYTE PRODUCTION - Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.04-28-2011
20120003739POPULATIONS OF EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN AND METHODS OF GENERATING SAME - A population of expanded adult islet beta cells is provided as well as a population of expanded and redifferentiated adult islet beta cells. Methods of generation of the populations of cells are provided.01-05-2012
20100028999METHODS, APPARATUS, AND SYSTEMS FOR FABRICATION OF POLYMERIC NANO- AND MICRO-FIBERS IN ALIGNED CONFIGURATIONS - Provided herein are apparatus and systems for fabricating highly aligned arrays of polymeric fibers having isodiameters ranging from sub 50 nm to microns with lengths of several millimeters. The approach disclosed herein uses (e.g.) a micropipette to deliver polymeric solution which is collected in the form of aligned fibers on a rotating and linearly translating substrate. The methods deposit polymeric fibers on spherical surfaces and gapped surfaces with precise control, thus heralding new opportunities for a variety of applications employing polymeric fibers. The design workspace for depositing fibers disclosed herein is dependent upon processing parameters of rotational/linear translational speeds and material properties of solution rheologies. Techniques for fabrication of multilayer fiber arrays, for fabrication of cell growth scaffolds and for attachment of particles to the fiber arrays are also disclosed.02-04-2010
20120045831POLY(LACTIC-GLYCOLIC)ACID CROSS LINKED ALENDRONATE (PLGA-ALN) A SHORT TERM CONTROLLED RELEASE SYSTEM FOR STEM CELL DIFFERENTIATION AND DRUG DELIVERY - The present invention relates to a bisphosphonates and synthetic polymeric carriers to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising activation of the synthetic polymeric carriers and the cross linking reaction. The present invention further provides methods for enhancing stem cell differentiation into osteogenic lineage and chondrogenic lineage, which comprise culturing a population of stem cells in specific micro-environments.02-23-2012
20120009681PLATFORM OF DENDRITIC CELL (DC)-BASED VACCINATION - The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.01-12-2012
20090029469Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens - A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.01-29-2009
20090263897REISHI F3 SUB FRACTION POLYSACCHARIDES AND METHODS OF USING SAME - The present disclosure relates to the discovery of methods of isolating subfractions of an F3 Reishi extract, and of administration of these novel isolates to eukaryotic cells in order to induce certain immumodulatory, hematopoeitic and tumor-inhibiting phenotypic changes in those eukaryotic cells, mediated through particular toll-like receptor (TLR) and other transmembrane receptors. F3 subfractions F301 and F331 have demonstrated that F331 is capable of activating at least TLR-2 while F301 is capable of activating at least TLR-2, TLR-4, and TLR-5.10-22-2009
20100190250Methods of Rejuvenating Cells In Vitro and In Vivo - The present invention provides methods for rejuvenating cells, tissues and the whole body. Also provided are rejuvenating buffers and agents as well as kits for rejuvenating cells. Also provided are methods for dedifferentiating somatic cells and differentiating the cells into other cell types.07-29-2010
20090280564METHOD FOR INDUCING DIFFERENTIATION OF MESODERMAL STEM CELLS, ES CELLS, OR IMMORTALIZED MESODERMAL STEM CELLS INTO NEURAL CELLS - Mesodermal stem cells or ES cells, prepared from the mononuclear cell fraction isolated from bone marrow fluid or umbilical blood, were found to differentiate into neural stem cells, neurons, or glial cells when cultured in a basal culture medium. In addition, the differentiation of the mesodermal stem cells or ES cells into neural cells was promoted through the addition of an ischemic brain extract to the above-mentioned basal culture medium. Furthermore, the neural cells obtained using the above-described method for inducing differentiation were revealed to have neural regeneration potency in a brain infarction model, a dementia model, a spinal cord injury model and a demyelination model.11-12-2009
20120064627APPARATUS AND METHOD FOR CULTURING STEM CELLS - A method is provided to prepare a plurality of microwells suitable for the formation of embryoid bodies from embryonic stem cells. The method requires applying an image-forming material to a heat sensitive thermoplastic material in a designed pattern and heating the material under conditions that reduce the size of the receptive material by at least about 60% to create a mold. A polymer such as PDMS is then applied to the mold and removed to form the microwells. In an alternative aspect, the plurality of microwells on receptive material are prepared by etching a microwell designed pattern into a heat sensitive thermoplastic material support and then heating the material under conditions that reduce the size of the receptive material by at least about 60%.03-15-2012
20120070897Method For Enucleating Nucleated Erythrocyte, And Enucleation Inducer - Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.03-22-2012
20120156778METHOD FOR EFFICIENT PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS UTILIZING CELLS DERIVED FROM ORAL MUCOSA - A main object of the present invention is to provide a technique to produce iPS cells with less burden on the patient and with high establishment efficiency. iPS cells can be efficiently produced with significantly improved establishment efficiency by selecting cells derived from oral mucosa and introducing, into the cells, reprogramming factors capable of inducing the cells into pluripotent stem cells.06-21-2012
20110091971Differentiation of Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage. The present invention also provides methods to generate and purify agents capable of differentiating pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.04-21-2011
20110065190BLOOD PLATELET INDUCTION METHOD - A novel induction method that effectively produces platelets from platelet precursor cells (e.g., hemopoietic stem/precursor cells) is disclosed. The method includes culturing platelet precursor cells in a culture solution in which a composite membrane is immersed so that the platelet precursor cells differentiate into platelets, the composite membrane including a porous support membrane and a porous thin membrane, the porous thin membrane being stacked on at least one side of the porous support membrane.03-17-2011
20090017539METHODS AND MEANS FOR STEM CELL PROLIFERATION AND SUBSEQUENT GENERATION AND EXPANSION OF PROGENITOR CELLS, AS WELL AS PRODUCTION OF EFFECTOR CELLS AS CLINICAL THERAPEUTICS - The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.01-15-2009
20100093091Undifferentiated Stem Cell Culture Systems - The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.04-15-2010
20100093088RETINOID COMPOUNDS AND THEIR USE - The invention relates to retinoid compounds of the formula (I):04-15-2010
20120122218Harnessing Cell Dynamics to Engineer Materials - The invention features synthetic materials and methods for inducing cell behavior. Matrix materials induce cell differentiation and cell manipulation based on mechanical and physical characteristics of the materials rather than chemical characteristics.05-17-2012
20100248366Synthetic Surfaces for Differentiating Stem Cells into Cardiomyocytes - Synthetic surfaces capable of supporting culture of eukaryotic cells including stem cells and undifferentiated human embryonic stem cells in a chemically defined medium include a swellable (meth)acrylate layer and a polypeptide conjugated to the swellable (meth)acrylate layer. The swellable (meth)acrylate layer may be formed by polymerizing monomers in a composition that includes a carboxyl group-containing (meth)acrylate monomer, a cross-linking (di- or higher-functional) (meth)acrylate monomer, and a hydrophilic monomer capable of polymerizing with the carboxyl group-containing (meth)acrylate monomer and the cross-linking (meth)acrylate monomer. The swellable (meth)acrylate layer has an equilibrium water content in water of between about 5% and about 70%. The conjugated peptide may include an RGD amino acid sequence.09-30-2010
20120129256METHOD OF PREPARING PLURIPOTENT STEM CELLS - The invention relates to biotechnology, and particularly to the preparation of pluripotent stem cells. The method involves introduction into umbilical cord and placental stem cells of RNA with at least one sequence which ensures the transition of cells to the pluripotent state. The method enables to effectively prepare pluripotent stem cells from the cells of mammalian placenta and umbilical cord which have not yet acquired somatic mutations, which reduces the risk of oncogenesis and other adverse effects of reprogramming.05-24-2012
20120164731METHOD OF INDUCING DIFFERENTIATION FROM PLURIPOTENT STEM CELLS TO SKELETAL MUSCLE PROGENITOR CELLS - Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the presence of Activin A, to allow the cell to differentiate into a PDGFRα-positive mesodermal cell, and the step 2) of culturing the mesodermal cell under serum-free conditions, and in the presence of a Wnt signal inducer, to allow the cell to differentiate into a skeletal muscle progenitor cell. Also provided are a cell population containing a skeletal muscle progenitor cell as obtained by the method, and a skeletal muscle regeneration promoting agent and therapeutic agent for muscular diseases such as muscular dystrophy, the promoting agent or agent comprising the skeletal muscle progenitor cell as an active ingredient.06-28-2012
20120315701PEPTIDE INHIBITING DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS OR HEMATOPOIETIC PRECURSOR CELLS AND USE OF SAME - The present invention provides a novel peptide that can be effectively used to produce or grow tissue-specific stem cells or tissue-specific progenitor cells in vitro. The peptide of the invention is a peptide having an amino acid sequence consisting of the amino acid residues set forth in SEQ ID NO:1, or an analog thereof. A feature of the peptide of the invention is having at least one of the following effects: (1) an effect of inhibiting differentiation of hematopoietic stem cells or hematopoietic progenitor cells into myeloid cells, (2) an effect of promoting amplification of mesenchymal stem cells, and (3) an effect of inducing hematopoietic stem cells from pluripotent stem cells.12-13-2012
20100173414Methods of Deriving Differentiated Cells from Stem Cells - The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells.07-08-2010
20120077271DIFFERENTIATION OF MULTI-LINEAGE PROGENITOR CELLS TO CHONDROCYTES - Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into chondrocytes.03-29-2012
20120214236GENERATING INDUCED PLURIPOTENT STEM CELLS AND PROGENITOR CELLS FROM FIBROBLASTS - The present disclosure provides a method of generating progenitor cells, such as hematopoietic or neural progenitor cells, from fibroblasts, such as dermal fibroblasts, comprising providing fibroblasts that express or are treated with a POU domain containing gene or protein and culturing the cells under conditions that allow production of progenitor cells, without traversing the pluripotent state. Also provided is a method of isolating a subpopulation of fibroblasts with reprogramming potential comprising providing fibroblasts that express an Oct-4-reporter and isolating cells that are positive for the reporter. Further provided is a method of generating reprogrammed fibroblast-derived induced pluripotent stem cells. Also provided are uses and assays of the cells produced by the methods of the disclosure.08-23-2012
20100009447Vgamma9Vdelta2 T cell proliferation agent, method for producing activated Vgamma9Vdelta2 T cells, and uses thereof - A Vγ9Vδ2 T cell proliferation agent includes at least a bisphosphonate, interleukin 2, and interleukin 18. Since has properties that improve cell viability by inhibiting cell death, IL-18 is presumably capable of acting as a cofactor for the bisphosphonate so as to significantly increase the effect of Vγ9Vδ2 T cell proliferation by the bisphosphonate and the IL-2. This allows providing a Vγ9Vδ2 T cell proliferation agent capable of growing Vγ9Vδ2 T cells with a proliferated efficiency significantly high compared to conventional methods so that the proliferated Vγ9Vδ2 T cells have a high antitumor activity and high cytokine productivity.01-14-2010
20090325293TREATMENT OF PLURIPOTENT CELLS - The present invention is directed to methods to treat pluripotent cells, whereby the pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of GSK-3B enzyme activity.12-31-2009
20120190112Differentiation of Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.07-26-2012
20120190111Differentiation of Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.07-26-2012
20080318315Reverse-Flow Perfusion of Three-Dimensional Scaffolds - The invention is a reverse-flow method and system for the loading, proliferation and differentiation of cells into and throughout an implantable biocompatible three-dimensional scaffold.12-25-2008
20120094384USE OF COMPOUNDS FOR DIFFERENTIATION OF CELLS - The present invention provides a method for differentiating an undifferentiated cell, said method comprising contacting an undifferentiated cell with certain compounds of Formula (I) or a salt thereof.04-19-2012
20110263017TECHNIQUE FOR REGULATING REGENRATION OF TISSUE OR FAULTY OR ABNORMAL PART IN ORGAN USING NELL-1 - The object aims to form and maintain a cell, a tissue or an organ induced by differentiation. Disclosed is a composition for inducing the differentiation of a cell capable of being differentiated in a given direction to thereby produce a cell, a tissue or an organ through the further induction of the differentiation in the given direction. The composition comprises NELL-1 or a substance which can be altered so as to act as NELL-1 upon the differentiation. Also disclosed is a composition for maintaining a cell, a tissue or an organ produced by the induction of the differentiation.10-27-2011
20120088302Cell Culture - A method for determining the effect of a plurality of culture conditions on a cell, comprising the steps of a) providing a first set of groups of cell units each comprising one or more cells, and exposing said groups to desired culture conditions; (b) pooling two or more of said groups to form at least one second pool; (c) subdividing the second pool to create a further set of groups of cell units; (d) exposing said further groups to desired culture conditions; (e) optionally, repeating steps (b)-(d) iteratively as required; and (f) optionally assessing the effect on a given cell unit of the culture conditions to which it has been exposed.04-12-2012
20120329155MEDIUM FOR MAMMALIAN SOMATIC CELLS AND ADDITIVE THEREFOR - Disclosed are a medium for mammalian somatic cells with which mammalian somatic cells can be grown effectively when the mammalian somatic cells are cultured, while reducing the amount of serum to be added to the medium as much as possible or without adding serum thereto, and an additive to constitute the medium. By blending of a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor to a medium, somatic cells of mammals can be grown even in cases where the medium does not contain serum at all or contains only a small amount thereof.12-27-2012
20120100610REVASCULARIZATION CELLS DERIVED FROM MONONUCLEAR CELLS, AND METHOD OF INDUCING DIFFERENTIATION THEREOF - The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD1104-26-2012
20120288936METHODS FOR REPROGRAMMING CELLS AND USES THEREOF - Described herein are methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming. Also descried are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro reprogramming. In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs). Also described are methods for generating these cells from human somatic cells and other types of cells. Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.11-15-2012
20130011924METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MESODERMAL CELLS - The present invention provides a method for inducing differentiation of pluripotent stem cells into mesodermal cells, comprising the step of culturing pluripotent stem cells in a serum-free medium without forming an embryoid body and without coculturing with cells from a different species.01-10-2013
20120149110PROCESS FOR PRODUCTION OF BIOARTIFICIAL ORGAN - A method for inducing the differentiation of stem cells into tissue cells; a bioartificial organ, which contains the tissue cells; and a material for medical purposes, which contains the bioartificial organ are disclosed. Stem cells capable of proliferation, self-replication and differentiation are used and cultured by a hanging-drop method to three-dimensionally construct a cell mass of embryoid bodies, and the cell mass is cultured in the presence of HGF, GDNF, b-FGF, BMP7 and EGF. In this manner, the stem cells can be differentiated into tissue cells. A bioartificial organ can be produced using cells that have been differentiated into the tissue cells. Further, a material for medical purposes can be provided.06-14-2012
20130017604USE OF ADIPOSE TISSUE-DERIVED STROMAL CELLS FOR CHONDROCYTE DIFFERENTIATION AND CARTILAGE REPAIR - Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.01-17-2013
20130017605ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF - A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene represented by SIR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising, dimethoxy-3,4′-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 and 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I and (ii) 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by are also disclosed. An additional embodiment, also discloses the enhanced anti-01-17-2013
20080248570Complexes of hyaluronans, other matrix components, hormones and growth factors for maintenance, expansion and/or differentiation of cells - A method is provided of propagating hepatic cells including hepatic progenitors ex vivo on or in hyaluronans with or without other extracellular matrix components (such as collagens, basal adhesion molecules, proteoglycans or their glycosaminoglycans) and with or without hormones and/or growth factors. Compositions comprising the matrix are also disclosed. Also, the complex can be used for ex vivo tissue engineering or can be used as a scaffold for grafts of cells to be transplanted in vivo.10-09-2008
20080233648BIASING OF CELLS TOWARD RETINAL, CORNEAL OR LENS DEVELOPMENT - Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells or mesenchymal stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.09-25-2008
20080227202Method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on a synthetic tubular structure - A method of promoting differentiation of one or more human stem cells into human coronary endothelial cells on at least one surface of a synthetic tubular structure to be used to make a human hybrid hemodialysis access graft is provided. The method includes arranging a plurality of human stem cells on the synthetic tubular structure to yield a hybrid stem cell/synthetic tubular structure and subjecting ex vivo, the hybrid stem cell/synthetic tubular structure to three dimensional dynamic conditions effective to promote differentiation of the one or more human stem cells into human coronary endothelial cells on the at least one surface.09-18-2008
20110263018CORE-SHELL STRUCTURED DELIVERY SYSTEM FOR GROWTH FACTORS, A PREPARATION METHOD THEREOF, AND USE THEREOF FOR THE DIFFERENTIATION OR PROLIFERATION OF CELLS - The present invention relates to a method of preparing a delivery system capable of loading bioactive growth factors that are essential for the differentiation and proliferation of cells and is characterized as loading at least two types of components comprising growth factors in a single carrier, whereby the release of each of the plurality of growth factors can be temporally controlled. Specifically, the method of preparing a microcapsule type growth factor delivery system according to the present invention includes: (1) preparing a polymeric microsphere comprising a first component, and then encapsulating the microspheres by electrodropping the polymer microsphere into another polymer comprising a second component, thereby manufacturing a core-shell structured, microcapsule type delivery system, or (2) encapsulating a polymer solution comprising a first component by electrodropping the polymer solution into another polymer comprising a second component, thereby manufacturing a core-shell structured microcapsule type delivery system. The present invention also provides a stem cell differentiation method involving bringing a microcapsule type delivery system loaded with multiple growth factors according to the present invention into contact with stem cells.10-27-2011
20080220521SHEET FOR GUIDING REGENERATION OF MESENCHYMAL TISSUE AND PRODUCTION METHOD THEREOF - To provide a sheet for guiding regeneration of mesenchymal tissue having improved formability, strength, absorbability and efficiency, the sheet is produced by steps of containing a culture medium in a surface of a porous sheet produced by freezing a bioabsorbable polymer material dissolved with an organic solvent and drying it, seeding a mesenchymal cell grown after taking from biotissue, and differentiating the mesenchymal cell to a mesenchymal tissue precursor cell, where the mesenchymal tissue precursor cell and an extracellular substrate are adhered on the surface of the porous sheet containing a culture medium, and the extracellular substrate is secreted in a process of the mesenchymal cell being differentiated to the mesenchymal tissue precursor cell.09-11-2008
20120252120DIAZONIUM SALT MODIFICATION OF SILK POLYMER - A method for modifying silk polymer by coupling a chemical moiety to a tyrosine residue of a silk polymer is described herein for the purpose of altering the physical properties of the silk protein. Thus, silk proteins with desired physical properties can be produced by the methods described herein. These methods are particularly useful when the introduction of cells to a mammal is desired, since modifications to the silk protein affect the physical properties and thus the adhesion, metabolic activity and cell morphology of the desired cells. The silk protein can be modified to produce, or modify, a structure that provides an optimal environment for the desired cells.10-04-2012
20110269231PROTEOGLYCAN-BINDING PEPTIDES THAT MODULATE STEM CELL BEHAVIOR - Biomaterials presenting synthetic peptides and methods of preparing biomaterials are disclosed. More particularly, the disclosure is directed to biomaterials including a substrate including a synthetic peptide thereon, wherein the synthetic peptide is selected from synthetic proteoglycan-binding peptides, synthetic glycosaminoglycan-binding peptides, and combinations thereof. The present disclosure is further directed to methods of preparing the biomaterials for use in sequestering endogenous proteoglycans and endogenous glycosaminoglycans, increasing stem cell proliferation, reducing spontaneous stem cell differentiation, and enhancing induced osteogenic differentiation of mesenchymal stem cells.11-03-2011
20130177985DNA Sequence Encoding a Retinoic Acid Regulated Protein - The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.07-11-2013
20130137176Biomatrix Scaffolds for Industrial Scale Dispersal - The present invention provides biomatrix scaffolds for industrial scale dispersal.05-30-2013
20130137177PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE OR DERIVATIVE THEREOF - Provided are a method of preparing a zinc oxide nanostructure electrode and a method of preparing a dye-sensitized solar cell using the same.05-30-2013
20090142833Pine Cone Extracts and Uses Thereof - A method of producing a pine cone extract and the pine cone extract produced there from, wherein the pine cone extract is useful in increasing the effects of nucleic acid vaccines and medicaments; and useful in the production of phenotypically immature and/or mature dendritic and/or fibrocyte cells.06-04-2009
20130157365INDUCED PLURIPOTENT STEM CELLS FROM HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human umbilical cord tissue-derived cell. More particularly, we have disclosed a human umbilical cord tissue-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages.06-20-2013
20130189785GENERATION OF CARDIOMYOCYTES FROM HUMAN PLURIPOTENT STEM CELLS - Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt/β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt/β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.07-25-2013
20080293137COMPOUNDS THAT ABROGATE DNA DAMAGE INDUCED CELL CYCLE G2 CHECKPOINT AND/OR AUGMENT ANTI-CANCER ACTIVITY OF DNA-DAMAGING TREATMENTS - The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.11-27-2008
20120021519EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS - The disclosure features a method of producing a reprogrammed cell (e.g. an induced pluripotent stem cell or an undifferentiated cell) from a differentiated (e.g. somatic) cell. In some embodiments, the methods includes contacting a differentiated (e.g. somatic cell) with a TGFBR1 inhibitor or anti-TGF-β-antibody to produce a reprogrammed cell (e.g. pluripotent stem cell or undifferentiated cell). Embodiments of the present invention relate to a reprogrammed cell and methods and compositions for producing a chemically produced reprogrammed cell or populations thereof.01-26-2012
20120021518GROWTH FACTOR HOMOLOG ZVEGF4 - Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.01-26-2012
20120021517Bacterial Mediated Delivery of Nuclear Protein Into Pluripotent and Differentiated Cells - A modified 01-26-2012
20120028354SYSTEMS AND METHODS FOR MAKING HEPATOCYTES FROM EXTRAHEPATIC SOMATIC STEM CELLS AND USE THEREOF - A method for preparing isolated hepatocytes is disclosed. The method comprises: a) culturing mesenchymal stem cells (MSCs) in a medium comprising hepatic growth factor (HGF) to cause the MSCs to differentiate toward hepatocytes, wherein the MSCs are isolated from bone marrow or umbilical cord blood; b) culturing cells from a) in a medium comprising HGF and oncostatin M (OSM) to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising OSM to cause the differentiated cells to mature into hepatocytes, and thereby producing the isolated hepatocyte cells.02-02-2012
20130196436CARDIOMYOCYTE PRODUCTION - Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.08-01-2013
20130196435STENCIL PATTERNING METHODS AND APPARATUS FOR GENERATING HIGHLY UNIFORM STEM CELL COLONIES - A method for producing highly uniform cell colonies in a cell culture dish with the use of stencils made from an elastomeric sheet sized to fit within the cell culture dish, having a singular opening or a plurality of openings of a number, pitch and diameter configured to optimally control the geometric growth parameters of a cell colony. The uniform cell colonies are produced by placing the stencil in a cell culture dish and hydropilizing the stencil. The stencil is overlayed with cell culture media and seeded with seed cells that are preferably grown for at least a day before the stencil is removed to produce a pattern of seeded cells with controlled pitch, colony diameter and density within the culture dish that grow to become highly uniform cell colonies. A kit with culture dish, stencil, culture media and growth media is also provided.08-01-2013
20130196437CARDIOMYOCYTE PRODUCTION - Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.08-01-2013
20120045832MULTIPOTENT NEURAL STEM CELLS - An isolated multipotent neural stem cells has a phenotype identified by expression of the protein β-tubulin IV and Olig2 and the absence of the proteins NG2, PLP, and GFAP.02-23-2012
20130210145GENERATION OF INNER EAR CELLS - Methods for generating cells of the inner ear, e.g., hair cells and supporting cells, from stem cells, e.g., mesenchymal stem cells, are provided, as well as compositions including the inner ear cells. Methods for the therapeutic use of the inner ear cells for the treatment of hearing loss are also described.08-15-2013
20130210146Methods and Compositions for Generation of Induced Pluripotent Stem Cells By RNAA - The present disclosure provides methods for inducing somatic cells to form induced pluripotent stem (iPS) cells. The method includes introducing a small activating RNA (saRNA) molecule into the somatic cell, where the saRNA molecule increases transcription of a transcription factor that induces the formation of induced pluripotent stem cells. The present disclosure also provides compositions and kits comprising a saRNA molecule that increases transcription of a transcription factor that induces the formation of induced pluripotent stem cells. The present disclosure provides iPS cells comprising at least one exogenous saRNA molecule, where the saRNA molecule increases transcription of a transcription factor that induces the formation of induced pluripotent stem cells.08-15-2013
20130210147Bioactive amino acid sequence and use therefrom - Use of the amino acid sequence Har-Gly-Asp (hRGD) as a bioactive sequence in functional peptides to promote cell adhesion, cell growth, and/or cell differentiation, and in the preparation of hydrogels, preferably hydrogels for cell culture. A hydrogel comprising the hRGD sequence, especially a hydrogel wherein the hRGD sequence is part of the hydrogel scaffold.08-15-2013

Patent applications in class Method of altering the differentiation state of the cell